The US FDA has issued a safety communication regarding investigational FMT, warning that there is a risk of serious infection caused by the transfer of multidrug-resistant organisms.
Browsing: Research > Clinical
A study has revealed genetic variants associated with differing levels of protective antibodies produced after routine immunizations.
In this interview we speak to David Padley from the National Institute for Biological Standards and Control about his recent poster ‘Point-of-Care testing for HIV: specialist quality control materials are a necessity’, presented at ECCMID 2019.
A global genomic survey of Streptococcus pneumoniae has identified 621 strains across 50 countries and has highlighted how the bacteria can evolve in response to vaccination.
A report analyzing the prevalence and incidence of chlamydia, gonorrhea, trichomoniasis and syphilis for 2016 has reported that rates of these four curable sexually transmitted infections remain high, estimating 376.4 million cases in 2016.
ECCMID 2019 saw the first presentation of the results from ASPECT-NP, a randomized, multi-center Phase III trial evaluating Merck’s ZERBAXA® (ceftolozane–tazobactam) for the treatment of patients with ventilated nosocomial pneumonia. In light of this we spoke to investigators Marin Kollef and Ignacio Martin-Loeches about the rationale behind this trial, its design and the key findings.
New research has assessed a genetically engineered fungus for the control of malaria mosquitoes in the first semi-field trial, demonstrating that populations were reduced by more than 99%.
Take a look at this month’s industry headlines including US FDA approvals for Mavyret (hepatitis C) and Dengvaxia, a rejection for Contepo and profits for Gilead Sciences.
Over 800,000 individuals will be vaccinated against cholera in North Kivu, Democratic Republic of Congo, as the area suffers an unprecedented combination of epidemics.